KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer
Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspects of KORU Medical's global commercial strategy—including marketing, sales, market access, and pharmaceutical customer engagement.
Adam joins KORU Medical from Becton Dickinson (BD), where he most recently served as Vice President and General Manager, Advanced Drug Delivery Systems, leading growth initiatives across the injectable drug delivery platform. Prior to BD, Adam served as Chief Executive Officer of ZebraSci, a specialized provider of analytical and drug device combination product development services to pharmaceutical companies, where he led a successful turnaround and growth strategy resulting in an eventual acquisition of the company by BD. He also held global leadership roles at Terumo Medical Corporation, including Worldwide Director of Marketing and Worldwide Director of Business Development, where he helped shape the company's global drug delivery strategy. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology, and an MBA with concentrations in Finance and Healthcare from Columbia Business School.
'Adam is a highly accomplished commercial leader with a strong presence in the market and deep customer relationships that have driven tangible business growth,' said Linda Tharby, President and CEO of KORU Medical. 'He combines strategic discipline with entrepreneurial agility and a proven track record of creating shareholder value. Equally important, Adam is a strong cultural fit—he leads with humility, builds trust with teams and customers alike, and brings a sharp focus on execution. We are thrilled to welcome him to the KORU leadership team.'
Mr. Kalbermatten added, 'I'm excited to join KORU at this pivotal moment. The company's dedication to patient-centered innovation and its culture of collaboration make it a truly inspiring place to lead and grow. With favorable market dynamics for subcutaneous delivery and a clear value proposition, KORU is well positioned to expand its impact. I'm excited to work alongside the talented team to drive continued momentum and deliver meaningful value to patients, providers, and shareholders.'
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the 'Freedom System') currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
'Pharma Bro' Martin Shkreli Bets Against Soaring Newegg, But Stock Keeps Climbing
Newegg Commerce Inc. (NASDAQ:NEGG) shares skyrocketed over 22% in Wednesday's session, extending a volatile run that has seen the stock swing dramatically this year. The surge came as the company expanded its stock sale program, addressed issues tied to a shareholder loan foreclosure, and added its chief executive to the board while insider share sales continued. The company said its board's Pricing Committee approved the sale of an additional 500,000 common shares on Aug. 17 under a $65 million Sales Agreement with Needham & Company. Newegg had already raised $29.3 million in gross proceeds by selling one million shares in mid-July. The company may adjust the number of shares sold depending on available authorizations. Fred Chang, Newegg's second-largest shareholder, defaulted on loans backed by nearly two million pledged shares. East West Bank foreclosed on about 660,000 of those shares in June and is pursuing another 100,000 to cover roughly $6.5 million owed by Chang's affiliate, Tekhill USA Chang's resignation from the board in July, shareholders elected CEO Anthony Chow on Aug. 9 to fill the vacancy. Chow has led the company since 2020 and holds an Executive MBA from UCLA's Anderson School of Management. Separately, insider filings show Yong Feng Hou, also listed as Montaque Hou, disclosed the planned sale of 150 shares valued at about $13,200 on Aug. 20. He has regularly sold small blocks of stock this month, with Fidelity Brokerage Services acting as broker. The stock has also attracted short sellers. Former pharmaceutical executive Martin Shkreli recently said he was betting against Newegg after its rally of more than 1,300% this year, calling it 'close to worthless.' Read more on that development here. Wednesday's rally pushed NEGG closer to its 52-week high of $133.00, far above its low of $3.32. The stock is trading roughly 173% above its 50-day simple moving average and more than 580% above its 200-day. Price Action: NEGG shares were trading higher by 22.61% to $109.61 at last check Wednesday. Read Next:Photo by Casimiro PT via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article 'Pharma Bro' Martin Shkreli Bets Against Soaring Newegg, But Stock Keeps Climbing originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27 minutes ago
- Business Wire
KBRA Comments on TowneBank's Merger Agreement to Acquire Dogwood State Bank
NEW YORK--(BUSINESS WIRE)--On August 19, 2025, Portsmouth, VA-based TowneBank (NASDAQ: TOWN)(KBRA Senior Unsecured Debt rating: A-/Stable Outlook) announced a definitive acquisition agreement with Raleigh, NC-based Dogwood State Bank, (OTC: DSBX, "Dogwood", $2.4 billion assets, $2 billion deposits) in an all-stock deal valued at $476.2 million (or $25.04/share of DSBX common stock, based on TOWN's 15-day average closing stock price of $35.77 on August 18, 2025), reflective of a price to TBV of 2.1x. The merger is expected to close in 1Q26. The proforma bank will have $22 billion in assets, $16 billion in loans, and $19 billion in deposits including the pending acquisition of Old Point Financial Corporation (expected to close September 1, 2025). This transaction would represent three closed acquisitions within a one-year time frame for TOWN. The acquisition significantly enhances TOWN's presence in North Carolina and South Carolina, two of the fastest-growing regions in the U.S. Further, the deal provides TOWN with the market leadership and scale as Dogwood has 17 retail branches in attractive markets including Raleigh, Charlotte, Greenville (NC), Wilmington, and Charleston (SC), complementing TOWN's existing Carolinas presence. Together, the combined entity will have a meaningful footprint across the top 5 Carolinas MSAs, including Charlotte, Raleigh, Greenville, and Charleston. Dogwood specializes in providing lending services (namely SBA lending) to small businesses through its small business lending division which will be complementary to TOWN's various existing business lines. While Dogwood's revenue mix is largely spread based (~80% - 85%), the addition of its SBA lending provides TOWN an additional fee generating business line (noninterest income has tracked near 40% of TOWN's total revenues in recent quarters). Dogwood's higher-yielding loan portfolio (6.81% for 2Q25) was slanted towards C&I, which represented 40% of total loans at 2Q25 (includes owner-occupied CRE), with non-owner occupied CRE comprising 28% (includes multi-family) and C&D at 10%. Additionally, with its focus on small business/SBA lending, Dogwood's loan portfolio carries a slightly elevated risk profile, though we note Dogwood's recent credit performance was generally in line with industry averages including an NCO ratio typically near 0.2%. Furthermore, TOWN has a long track record of peer-leading asset quality and a proven history of successful integration of past acquisitions. TOWN's loan review process covered 40% of Dogwood's loan portfolio with a diligent focus on its SBA lending and a credit mark of $22.5 million, or 1.2% of Dogwood's loans. The transaction also includes estimated interest rate marks of $38.1 million on the loan portfolio, $10.6 million on HTM securities, and $2.7 million on AOCI securities. Overall, the impact to TOWN's capital is expected to be moderate, with a reported proforma CET1 ratio of ~11% (we note that this proforma ratio includes the impact of the pending acquisition of Old Point Financial which is expected to close in 3Q25). With that said, TOWN has historically managed capital consistently at or above rated peer averages (CET1 ratio has generally ranged from 12% -13%). KBRA expects TOWN to rebuild capital closer to historical levels with enhanced profitability trends stemming from the pending transactions. Steve Jones, CEO of Dogwood, will remain in a key leadership position with the combined bank, assuming the role of President for TOWN's North Carolina and South Carolina banking operations supported by 75 seasoned bankers across the region. In addition, TOWN will appoint one director from DSBX to its board. As a reminder, TOWN recently announced the in-market acquisition of Old Point Financial Corporation ($1.5 billion assets) in a combination of stock and cash deal valued at ~$213 million, which is expected to close in 2H25. TOWN closed the Richmond, VA -based Village Bank and Trust Financial Corp ($748 million in assets) acquisition on April 1, 2025. This was an all-cash deal valued at $120 million. In our view, the acquisition of Dogwood State Bank represents a strategically significant expansion that strengthens TOWN's position within the fast-growing Carolinas corridor. The transaction broadens market penetration, enhances loan portfolio diversification, and bolsters the funding base with a greater proportion of low-cost deposits. About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010927
Yahoo
an hour ago
- Yahoo
HSBC cuts Goodyear to Hold as turnaround optimism fades
-- HSBC downgraded Goodyear Tire (NASDAQ:GT) & Rubber to Hold from Buy, saying weak earnings and limited pricing power have reduced confidence in the company's turnaround. The bank cut its price target to $9.50 from $15.50 after Goodyear's second-quarter results fell well short of expectations, with volumes down 5.5% and operating income dropping 53% year on year. HSBC said cost savings from restructuring efforts were largely offset by higher raw material costs and lower volumes, resulting in only modest net savings. While Goodyear expects price versus raw material swings to improve later this year, HSBC said it no longer sees a near-term re-rating story as likely. Most of its earlier optimism was based on a valuation catch-up with higher-quality peers, a scenario the analysts now say could take much longer to play out. HSBC lowered its earnings forecasts for 2025-27, noting that higher tariffs and ongoing cost pressures are likely to limit margin improvement even as raw material headwinds ease. It expects operating margin to reach 7.6% in 2026, only slightly above 2024 levels. Goodyear shares trade at a steep discount to top-tier tire makers, and HSBC said that gap is unlikely to close unless the company can deliver sustained gains in earnings and free cash flow. 'We still see potential for earnings improvement into 2026e, but we are less convinced in the rerating story after recent results,' the analysts wrote. Related articles HSBC cuts Goodyear to Hold as turnaround optimism fades Risks Rising? Smart Money Dodged 46%+ Drawdowns on These High-Flying Names After soaring 149%, this stock is back in our AI's favor - & already +25% in July
